Brunel University Research Archive(BURA) preserves and enables easy and open access to all
types of digital content. It showcases Brunel's research outputs.
Research contained within BURA is open access, although some publications may be subject
to publisher imposed embargoes. All awarded PhD theses are also archived on BURA.
Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/23946Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Schmidt, AF | - |
| dc.contributor.author | Hunt, NB | - |
| dc.contributor.author | Gordillo-Marañón, M | - |
| dc.contributor.author | Charoen, P | - |
| dc.contributor.author | Drenos, F | - |
| dc.contributor.author | Kivimaki, M | - |
| dc.contributor.author | Lawlor, DA | - |
| dc.contributor.author | Giambartolomei, C | - |
| dc.contributor.author | Papacosta, O | - |
| dc.contributor.author | Chaturvedi, N | - |
| dc.contributor.author | Bis, JC | - |
| dc.contributor.author | O’Donnell, CJ | - |
| dc.contributor.author | Wannamethee, G | - |
| dc.contributor.author | Wong, A | - |
| dc.contributor.author | Price, JF | - |
| dc.contributor.author | Hughes, AD | - |
| dc.contributor.author | Gaunt, TR | - |
| dc.contributor.author | Franceschini, N | - |
| dc.contributor.author | Mook-Kanamori, DO | - |
| dc.contributor.author | Zwierzyna, M | - |
| dc.contributor.author | Sofat, R | - |
| dc.contributor.author | Hingorani, AD | - |
| dc.contributor.author | Finan, C | - |
| dc.date.accessioned | 2022-01-15T09:44:44Z | - |
| dc.date.available | 2022-01-15T09:44:44Z | - |
| dc.date.issued | 2021-09-24 | - |
| dc.identifier | 5640 | - |
| dc.identifier.citation | Schmidt, A.F., Hunt, N.B., Gordillo-Marañón, M., Charoen, P., Drenos, F. et al. (2021) 'Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease', Nature Communications, 12, 5640, pp. 1-10. doi: 10.1038/s41467-021-25703-3. | en_US |
| dc.identifier.uri | https://bura.brunel.ac.uk/handle/2438/23946 | - |
| dc.description | The preliminary meta-analysis of RCT data were presented at BPS 2018 by NH. The preprint version of this paper has been deposited on medrxiv: https://doi.org/10.1101/2020.09.07.20189571. | en_US |
| dc.description.abstract | Copyright © 2021 The Author(s). Development of cholesteryl ester transfer protein (CETP) inhibitors for coronary heart disease (CHD) has yet to deliver licensed medicines. To distinguish compound from drug target failure, we compared evidence from clinical trials and drug target Mendelian randomization of CETP protein concentration, comparing this to Mendelian randomization of proprotein convertase subtilisin/kexin type 9 (PCSK9). We show that previous failures of CETP inhibitors are likely compound related, as illustrated by significant degrees of between-compound heterogeneity in effects on lipids, blood pressure, and clinical outcomes observed in trials. On-target CETP inhibition, assessed through Mendelian randomization, is expected to reduce the risk of CHD, heart failure, diabetes, and chronic kidney disease, while increasing the risk of age-related macular degeneration. In contrast, lower PCSK9 concentration is anticipated to decrease the risk of CHD, heart failure, atrial fibrillation, chronic kidney disease, multiple sclerosis, and stroke, while potentially increasing the risk of Alzheimer’s disease and asthma. Due to distinct effects on lipoprotein metabolite profiles, joint inhibition of CETP and PCSK9 may provide added benefit. In conclusion, we provide genetic evidence that CETP is an effective target for CHD prevention but with a potential on-target adverse effect on age-related macular degeneration. | en_US |
| dc.description.sponsorship | This research has been conducted using the UK Biobank Resource under Application Number 12113. The authors are grateful to UK Biobank participants. We gratefully acknowledge the support of UCLEB and CHARGE. Funding and role of funding sources: A.F.S. is supported by BHF grant PG/18/5033837 and the UCL BHF Research Accelerator AA/18/6/34223. C.F. and A.F.S. received additional support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre. M.G.M. is supported by a BHF Fellowship FS/17/70/33482. A.D.H. is an NIHR Senior Investigator. This work was supported by the UKRI/NIHR Strategic Priorities Award in Multimorbidity Research (MR/V033867/1). This work was additionally supported by a grant [R01 LM010098] from the National Institutes of Health (USA). We further acknowledge support from the Rosetrees and Stoneygate Trust. The UCLEB Consortium is supported by a British Heart Foundation Program Grant (RG/10/12/28456). T.R.G. receives support from the UK Medical Research Council (MC_UU_00011/4). D.O.M.K. is supported by the Dutch Science Organization (ZonMW-VENI Grant 916.14.023). A D.H. receives support from the UK Medical Research (MC_UU_12019/1). M.K. is supported by the Wellcome Trust (221854/Z/20/Z), the UK Medical Research Council (MR/S011676/1, MR/R024227/1), National Institute on Aging (NIH), US (R01AG062553), and the Academy of Finland (311492). D.A.L. is supported by a Bristol BHF Accelerator Award (AA/18/7/34219) and BHF Chair (CH/F/20/90003) and works in a unit that receives support from the University of Bristol and the UK Medical Research Council (MC_UU_00011/6). D.A.L. is a National Institute of Health Research Senior Investigator (NF-0616-10102). N.F. is supported by the National Institutes of Health (R01-MD012765, R01-DK117445, R21- HL140385). P.C. is supported by the Thailand Research Fund (MRG6280088. UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish Government, and the Northwest Regional Development Agency. It has also had funding from the Welsh Assembly Government and the British Heart Foundation. Infrastructure for the CHARGE Consortium is supported in part by the National Heart, Lung, and Blood Institute grant R01HL105756. | en_US |
| dc.format.extent | 1 - 10 | - |
| dc.format.medium | Electronic | - |
| dc.language.iso | en_US | en_US |
| dc.publisher | Springer Nature | en_US |
| dc.rights | Copyright © 2021 The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. | - |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
| dc.subject | cardiovascular diseases | en_US |
| dc.subject | clinical trial design | en_US |
| dc.subject | target validation | en_US |
| dc.title | Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | https://doi.org/10.1038/s41467-021-25703-3 | - |
| dc.relation.isPartOf | Nature Communications | - |
| pubs.issue | 1 | - |
| pubs.publication-status | Published | - |
| pubs.volume | 12 | - |
| dc.identifier.eissn | 2041-1723 | - |
| Appears in Collections: | Dept of Life Sciences Research Papers | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| FullText.pdf | 1.31 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License
